Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants

Hepatology

Volumn 45, Issue 1, 2007, Pages 111-117

  Jeffrey, Gary P ^a,b,e   MacQuillan, Gerry ^a,b   Chua, Fern ^c   Galhenage, Sam ^b   Bull, Judith ^b   Young, Emma ^b   Hulse, Gary ^d   O'Neil, George ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Sir Charles Gairdner Hospital   (United States)

^c Australian Medical Procedures Research Foundation (AMPRF)   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; BUPRENORPHINE; NALTREXONE; NEUROLEPTIC AGENT; OPIATE; PEGINTERFERON ALPHA2B; POLYLACTIDE; RIBAVIRIN;

ADULT; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DEPRESSION; DIARRHEA; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG DOSE REDUCTION; DRUG IMPLANT; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HAIR DISEASE; HAIR THINNING; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; INTRAVENOUS DRUG ABUSE; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; SIDE EFFECT; TABLET COMPRESSION; TABLET FORMULATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG IMPLANTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 33846418330     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21470     Document Type: Article

References (34)

1. Thomas DL. Hepatitis C epidemiology. Curr Top Microbiol Immunol 2000;242:25-41.
2. Zekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, et al. Liver transplantation for HCV associated liver cirrhosis: Recipient predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transplant 2003;9:339-347.
3. Buti M, San Miguel R, Brosa M, Cabases JM, Medina M, Angel Casado M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005;42:639-645.
4. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002;186:1558-1564.
5. Wodak A. Injecting nation: achieving control of hepatitis C in Australia. Drug Alcohol Rev 1997;16:275-284.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
7. Fried MW, Shiffman ML, Reddy KJ, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002;347:975-982.
8. National Institutes of Health Consensus Statement on Management of Hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements 2002;19.
9. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004;39:1147-1171.
10. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004;99:1167-1175.
11. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. HEPATOLOGY 2001;34:188-193.
12. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. HEPATOLOGY 2003;37:443-451.
13. Van Thiel DH, Anantharaju A, Creech MS. Response of treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003;98:2281-2288.
14. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005;29:159-165.
15. Kontorinis N, Young J, Garas G, Speers D, Chester BP, MacQuillan G,et al. Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic. Intern Med J 2003:33:500-504.
16. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. The Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD002209. DOI:10.1002/14651858.CD002209.
17. Caplehorn JRM, Ross MW. Methadone maintenance and the likelihood of risky needle-sharing. Int J Addict 1995;30:685-698.
18. Rawson RA, McCann MJ, Hasson AJ, Ling W. Addiction pharmacotherapy 2000: new options, new challenges. J of Pscychoactive Drugs 2003;32:371-377.
19. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet;1999;353:221-226.
20. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, O'Neil P. Blood naltrexone and 6-β-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 2004;9:59-65.
21. Hulse GK, O'Neil G, Hatton M, Paech MJ. Use of oral and implantable naltrexone in the management of the opioid impaired physician. Anaesth Intensive Care 2003;31:196-201.
22. Hulse GK, O'Neil G, Arnold-Reed DE. Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. International J of Gyn Obst 2004;85:170-171.
23. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.
24. Kamal AM, Fouly AE, Kamel RR, Hockenjos B, Tawil AA, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006;130:632-638.
25. Chang A, Skole K, Gautam M, Schmutz J, Black M, Thomas R, et al. The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005;22:701-706.
26. Tabone M, Sidoli L, Laudi C, Pellegrino S, Rocca G, Della Monica P, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 2002;9:288-294.
27. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, et al. Alcohol use and treatment of hepatitis C virus: results of a national multicentre study. Gastroenterology 2006;130:1607-1616.
28. Geber WF, Lefkowitz SS, Hung CY. Effect of morphine, hydromorphone, methadone, mescaline, trypan blue, vitamin A, sodium salicylate, and caffeine on the serum interferon level in response to viral infection. Arch Int Pharmacodyn Ther 1975;214:322-327.
29. Li Y, Zhang T, Douglas SD, Lai JP, Xiao WD, Pleasure DE, et al. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003;163:1167-1175.
30. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosupression: a review. Am J Ther 2004;11:354-365.
31. Golub ET, Latka M, Hagan H, Havens JR, Hudson SM, Kapadia F, et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health 2004;81:278-290.
32. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002;8:45-49.
33. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-83.
34. Asselah T, Vidaud D, Doloy A, Boyer N, Martinot M, Vidaud M, et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut 2003;52:900-902.